<DOC>
	<DOCNO>NCT02546674</DOCNO>
	<brief_summary>The main purpose study evaluation deep molecular response ( MR4.5 ; BCR-ABL IS &lt; 0.0032 % ) 24 month therapy nilotinib newly diagnose patient chronic phase CML . Via use MR4.5 EUTOS ( 'European Treatment Outcome Study CML ' ) laboratory adequate reliable molecular monitoring key parameter assess molecular milestone foster . Furthermore trial aim investigate early prediction outcome newly diagnose patient nilotinib assess individual decline BCR-ABL transcript . Quality life bemeasured via use EORTC CML-24 questionnaire .</brief_summary>
	<brief_title>Study Assessing Deep Molecular Response Adult Patients With CML Chronic Phase Treated With Nilotinib Firstline .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients newly diagnose ( within 6 month ) Philadelphia chromosome positive CML chronic phase ; Patients must previously untreated CML exception 6 month treatment hydroxyurea maximum 6 week treatment imatinib Known impair cardiac function like long QT syndrome , history myocardial infarction unstable angina past 12 month . Patients pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Molecular Response</keyword>
	<keyword>MR4.5</keyword>
</DOC>